Pfizer and BioNTech said Tuesday that they have initiated a clinical study to assesses the safety and efficacy of a COVID-19 vaccine for adults aged 18 to 55 years that specifically targets the omicron variant of SARS-CoV-2. The study will consist of 1,420 participants in three cohorts, including separate cohorts of people who have received two or three doses of the current Pfizer-BioNTech
BOSTON — The emergence of infectious diseases can be tied to events like climate change, social change and political trends, according to an expert. Heather…
ATLANTA — Pregnant women with fewer economic resources may still be at elevated risk for CVD despite a low score on a CVD risk calculator,…
ATLANTA — Data from a small substudy with cardiac MRI suggest acoramidis may improve both cardiac mass and function for adults with symptomatic transthyretin amyloid…
Chief scientist voices fears about H5N1 variant that has ‘extraordinarily high’ mortality rate in humans
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Even with the lessons learned from the recent COVID-19 pandemic, the US Department of Health and Human Services (HHS) failed…
In addition to suffering with cystic fibrosis, patients with this condition often contract lung infections that are difficult to treat; however, an upcoming study may…
The FDA has cleared an investigational new drug application for a small molecule therapeutic to treat those with Fragile X syndrome, according to the manufacturer.In…
Approximately 77,000 people in the U.S. have hypoparathyroidism due to absent or subphysiological levels of parathyroid hormone. About 75% of cases are the result of…
ATLANTA — Pregnant women with fewer economic resources may still be at elevated risk for CVD despite a low score on a CVD risk calculator,…
ATLANTA — Data from a small substudy with cardiac MRI suggest acoramidis may improve both cardiac mass and function for adults with symptomatic transthyretin amyloid…
